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Background: Sleep–wake disturbances have frequently been reported in bipolar disorder and 
schizophrenia, and are considered to be caused by an underlying circadian rhythm disorder. 
The study presented here was designed to investigate the existence of Per3 polymorphism in 
bipolar disorder type I (BD-I) and schizophrenic patients in South India.
Methods: Blood samples were collected from 311 BD-I patients, 293 schizophrenia patients, 
and 346 age- and sex-matched normal controls. Per3 genotyping was performed on DNA by 
polymerase chain reaction using specific primers.
Results: An increased prevalence of five repeat homozygotes was seen in BD-I patients as 
compared with healthy controls (odds ratio =1.72 [95% confidence interval: 1.08–2.76, P=0.02]). 
In BD-I patients, the frequency of the five repeat allele was higher (allele frequency =0.41), 
and that of the four repeat allele lower (allele frequency =0.36) (χ2=4.634; P,0.03) than in the 
control group. No significant association was observed in the allele frequencies of four and five 
repeat alleles in schizophrenia patients when compared with controls.
Conclusion: The occurrence of the five repeat allele of Per3 may be a risk factor for BD-I 
onset in this ethnic group.
Keywords: circadian rhythms, clock genes, Per3 polymorphism, bipolar disorder, schizo-
phrenia
Introduction
Most organisms have evolved an internal timekeeping system as a temporal program 
for adapting to the rhythmic environmental fluctuations which accrue from the earth’s 
rotation (eg, light–dark and temperature cycles). In humans this system involves, 
numerous behavioral and physiological parameters, including sleep–wake behavior 
and emotional and cognitive functioning, all of which oscillate rhythmically with a 
circadian pattern.1,2 There is a close interdependency between the circadian system 
and the body’s homeostatic mechanisms. There is evidence suggesting that circadian 
processes, involving 24-hour oscillations in sleep propensity, interact with homeo-
static mechanisms such as increases in sleep drive during wakefulness and reductions 
in drive during sleep.3,4 Consequently, the cross talk between these two systems is a 
reliable predictor of the sleep onset and offset of individuals.5,6
In certain psychiatric conditions, however, these rhythmicities may be disrupted. 
Sleep perturbations, reductions in sleep onset latency, early morning awakenings, 
and specifically disturbed rapid eye movement sleep have been observed in patients 
with the diagnosis of bipolar disorder (BD).7,8 Indeed, several reports have provided 
evidence suggesting that the desynchronization of the internal timekeeping system 
can be an important contributing factor in the onset of BD.9,10
Abnormal sleep–wake cycles, including changes in circadian phase (both advances 
and delays), discontinuous and compartmentalized sleep episodes, and disassembly 
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in rest–activity cycles, have also been observed in patients 
suffering from schizophrenia.11–13
A variable tandem repeat polymorphism coding for 
18 amino acids has been identified in exon 18 of Per3, 
a circadian clock gene involved in the regulation of the 
transcription–translation feedback loop generating 24-hour 
periodicity.14 This polymorphism has been linked to a 
variety of circadian and pathological phenomena. For 
example, there is evidence that Per3 length polymorphism 
is associated with sleep homeostasis and cognition,15 diurnal 
preference,16–18 and delayed sleep-phase syndrome.16,18
In one study, five repeat homozygotes of Per3 genotype 
were found to be associated with the onset of BD.19 By contrast, 
the postpartum onset of BD correlated with four repeat homozy-
gotes.20 Nievergelt et al21 reported evidence for the association of 
Per3 haplotypes with BD, whereas in their replicative study they 
did not find any association between manic-depressive illness 
and Per3 repeat polymorphism.22 In schizophrenia, two single 
nucleotide polymorphisms were reported to be associated with 
the disorder9 but no association of a Per3 repeat polymorphism 
was found in 148 ethnically Han Chinese schizophrenics.23 
In view of these conflicting reports, and to further clarify the 
role of Per3 in the etiology of BD and schizophrenia, we sought 
to investigate whether an association existed between Per3 
length polymorphism and bipolar disorder type I (BD-I) or 
schizophrenia in a group of South Indian patients. To the best 
of our knowledge, this is the first study on this matter to have 
been carried out in an Indian population.
Methods
ethics statement
All information with regard to the protocol was explained 
to the participants, and their written consent was obtained. 
The guidelines for the ethical treatment of patients in investi-
gational studies were followed24 and the experimental protocol 
was reviewed and approved by the Institutional Ethical Com-
mittee of the Madurai Kamaraj University.
sample collection
Blood samples (2 mL) were collected from patients suffering 
from BD-I (n=311, male =48.9%, female =51.1%) and schizo-
phrenia (n=293, male =61.4%, female =38.6%), and normal 
controls (n=346, male =53.2%, female =46.8%). The mean 
ages of participants in the three groups were 37.8±10.6 years 
(± standard deviation; BD-I patients), 36.4±10.1 years 
(schizophrenia patients), and 35.1±8.8 years (normal con-
trols). All BD-I and schizophrenia patients included in the 
study were either in- or outpatients of the MS Chellamuthu 
Trust and Research Foundation, located in Madurai city. 
Patient and control information was collected over 3 years. 
Clinical interviews of the patients were undertaken using the 
Mini-International Neuropsychiatric Interview25 and clinical 
histories of longstanding symptoms were taken. Diagnoses of 
patients were made by a trained psychiatrist and confirmed 
by a senior psychiatrist. More details about the patients, 
including symptoms and mood profile, were obtained from 
family members and/or a close relative.
Diagnostic and Statistical Manual of Mental Disorders, 
4th edition (DSM-IV) diagnostic criteria for schizophrenia 
included all subtypes (paranoid, disorganized, catatonic, 
undifferentiated, and residual); BD-I diagnostic criteria also 
included all six DSM-IV subtypes.26
All BD-I and schizophrenia patients were undergoing rou-
tine treatment for their respective disorders. Control subjects 
were initially screened and excluded from participation if 
they exhibited any symptoms of schizophrenia or mood disor-
ders, or if they reported that any of their first-degree relatives 
had such symptoms. Using unstructured interviews, healthy 
control subjects were selected after a psychiatric screening. 
No prescribed questionnaire was used to determine any type 
of symptom in the controls. Hospital staff, students, and staff 
of the university were selected as controls. Selected controls 
did not have any history of head injury, sleep disorders, or 
any other major disorder which could cause a bias. All the 
healthy controls and patients confirmed that they were of 
South Indian ancestry.
Per3 genotyping
DNA was isolated from participants’ blood samples 
using the phenol–chloroform method. A polymerase 
chain reaction (PCR) was performed using specific prim-
ers (5 ′-TGTCTTTTCATGTGCCCTTACTT-3′  and 
5′-TGTCTGGCATTGGAGTTTGA-3′) as described 
elsewhere.27 The PCR reaction was carried out in 10 µL tubes 
containing 1 µL of 1× PCR reaction buffer, 0.5 µL (0.5 mM) 
of deoxynucleotide triphosphates (dNTPs) mix, 1.5 µL 
(0.4 mM) forward/reverse primer mix, 0.05 µL (0.025 U) 
Taq polymerase enzyme (Genet Bio Co Ltd, Daejeon, 
South Korea), 2 µL (100 ng) of genomic DNA and 4.95 µL of 
Milli-Q® water. The PCR amplification conditions included 
an initial step of 94°C for 5 minutes, 40 cycles of amplifica-
tion (94°C for 30 seconds, 60.6°C for 30 seconds, 72°C for 
30 seconds), and a final extension at 72°C for 5 minutes. 
The resultant PCR products showed three genotypes based 
on their DNA size, characterized as 1) Per35/5 homozygous 
allele (401 bp), 2) Per34/4 homozygous allele (347 bp), and 
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3) Per34/5 heterozygous allele (347 and 401 bp) (Figure 1). 
Subsequently, the amplified DNA sequences were sequenced 
for further confirmation.
statistical analysis
The distributions of four and five repeat allele frequencies in 
the population were determined using the Hardy–Weinberg 
exact test.28 Deviations from Hardy–Weinberg equilibrium 
and the association of allele frequencies of four and five 
repeat alleles with BD-I, schizophrenia, and control subjects 
were analyzed by chi-square testing using SPSS software 
(v 20; IBM, Armonk, NY, USA). P-values of less than 0.05 
were taken as evidence of statistical significance.
Results
Biallelic repeat variants of Per3 in BD-I, schizophrenia, and 
control subjects are summarized in Table 1. The distribution 
of Per3 genotypes in BD-I, schizophrenia, and normal healthy 
individuals were within the limits of the Hardy–Weinberg 
equilibrium. The observed and expected allele frequencies 
of both alleles in the three groups were similar and no group 
varied from the limit. The observed genotype frequencies 
of the controls were 4/4=141, 4/5=163, and 5/5=42, and 
expected genotype frequencies were 4/4=143.1, 4/5=158.8, 
and 5/5=44.1, and they were similar and did not show any 
 statistical significance (P.0.05). Similarly, the observed gen-
otype frequencies of BD-I patients were 4/4=109, 4/5=146, 
and 5/5=56 and their expected genotype frequencies did 
not have any major difference (4/4=106.5, 4/5=150.9, and 
5/5=53.5) and did not exhibit statistical significance (P.0.05). 
Likewise, the observed (4/4=115, 4/5=137, and 5/5=41) and 
expected genotype frequencies (4/4=114.9, 4/5=137.2, and 
5/5=40.9) of the schizophrenia patients were similar and did 
not possess any significant difference (P.0.05).
An increased prevalence of five repeat homozygotes was 
seen in BD-I patients (odds ratio =1.72 [95% confidence inter-
val: 1.08–2.76, P=0.02]). The frequency of five repeat allele 
(allele frequency [AF] =0.41) was higher, and that of four 
repeat allele lower (AF =0.36), in BD-I patients (χ2=4.634, 
P,0.03) than in the control cohort (Table 1). The analysis 
of allele frequencies of four and five repeats did not reveal 
any statistically significant differences between patients with 
schizophrenia and the control group (χ2=0.385; P=0.53).
There were differences in the allele frequencies of Per3 and 
this observation was particularly notable among female patients 
with BD-I (χ2=4.532; P,0.05) (Table 2). No significant dif-
ferences were found in the allele frequencies of four and five 
repeat alleles in male and female schizophrenia patients when 
compared with male and female control groups (Table 3).
Discussion
The foregoing results support the conclusion that Per3 
 polymorphism is associated with BD-I but not with schizo-
phrenia. Benedetti et al19 reported an association between 
earlier onset of BD with five repeat allele in the homozygous 
state. Another study suggested an influence of Per3 poly-
morphism in the postpartum onset of BD;20 interestingly, in 
the latter investigation,20 four repeat homozygotes have been 
associated with bipolar episodes. However, no significant 
difference was observed in the onset and number of episodes 
between Per3 repeat alleles and BD.27
In a previous study, which used the Temperament and 
Character Inventory,29 five repeat homozygotes were found 
to be significantly linked with certain mood behaviors 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
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Figure 1 agarose gel showing Per3 alleles.
Notes: lane 1: 100 bp marker; lanes 2, 3, 5, and 8: 4/5 heterozygous allele (401 and 
347 bp); lanes 2–5: control samples; lanes 4, 6, and 9–13: 4/4 homozygous allele (347 
bp); lanes 5–13: bipolar disorder patient samples; lane 7: 5/5 homozygous allele (401 
bp); lane 14: no template control.
Table 1 genotypic distribution of the 4-/5-length polymorphism of Per3 in bipolar disorder type i (BD-i) and schizophrenia patients 
and controls
Group N Genotype, n (%) Allele, n (%) χ2 P
4-/4- 4-/5- 5-/5- 4- 5-
control 346 141 (40.8) 163 (47.1) 42 (12.1) 445 (0.64) 247 (0.36) 4.634 0.03*
BD-i 311 109 (35.1) 146 (47.0) 56 (18.0) 364 (0.59) 258 (0.41)
schizophrenia 293 115 (39.3) 137 (46.7) 41 (14.0) 367 (0.63) 219 (0.37) 0.385 0.53
Notes: 4-, 4-repeat allele; 5-, 5-repeat allele; *statistically significant.
Abbreviations: N, number of samples; n, number of genotypes and alleles.





including novelty seeking, extravagance, cooperativeness, 
compassion, and integrated conscience in a subset of bipo-
lar individuals.27 The genotype frequencies observed in 
the BD-I group in the present study (Per34/4 homozygous 
allele =35.0%, Per34/5 heterozygous allele =46.9%, and 
Per35/5 homozygous allele =18.0%) were closely similar to 
those reported previously in BD patients (35.3%, 46.5%, and 
18.2%, respectively).19
Control allele frequencies of four repeat (AF =0.64) was 
slightly higher than the allele frequency found in Hindus of 
Maharashtra, India (AF =0.57) (M Thomas, Department of 
Biology, University College London, personal communica-
tion, March, 2012) and slightly less than the mean of the global 
population (AF =0.68).30 As indicated by post-Hardy–Weinberg 
equilibrium testing, the genotype and allele frequencies in the 
three groups presumably remained undisturbed by selection 
force. Furthermore, no selective advantage was observed over 
any particular Per3 allele globally.30 In sex-based analysis, dif-
ferences in the allele frequencies of both male and female BD-I 
patients were observed when compared with control subjects. 
Although the sample size was small, the differences between 
the observed and expected allele frequencies of the female BD-I 
group were found to be statistically significant, whereas these 
differences did not reach significance in the male BD-I group.
Since the frequency of occurrence of the five repeat allele 
was significantly greater in BD-I patients than in control indi-
viduals, the high occurrence of five repeat allele frequency 
may be correlated with the behavioral phenotype of the 
corresponding allele. For instance, patients with five repeat 
homozygotes showed short sleep latencies and spent more 
time in slow wave sleep.15 Five repeat allele individuals also 
exhibited more depressive symptoms and a lower motiva-
tional level than those with a four repeat allele.31 Sleep–wake 
behaviors such as a short sleep duration, early bedtime and 
sleep onset, spending more time in bed, hypervigilance, and 
reduced daytime sleep durations have been observed more 
frequently in subjects with five repeat homozygotes than in 
those with four repeat homozygotes or heterozygotes.32
How the Per3 gene contributes to the pathogenesis of 
psychiatric disorders is still unclear. A possible explana-
tion for the occurrence of mood disorders is that in affected 
individuals, the circadian clock may show poor adaptability 
to different seasons.33,34 Another possible way in which a 
polymorphism of Per3 could influence mood is by affecting 
sleep.33,35 No previous study has shown evidence specifically 
linking the Per3 genotype to any mental health outcome 
measures.32 The evidence presented in the current study is 
consistent with the hypothesis that Per3 alleles could influ-
ence the mental health status of individuals by modulating the 
sleep phase. Relevant to this suggestion has been the finding 
of an association between a single nucleotide polymorphism 
of Per3 and poor sleep quality in BD patients.36 Morningness 
and eveningness preferences, which are strongly correlated 
with Per3, could modify the phase of the sleep and could 
conceivably result in abnormal mood profiles. In addition, 
Per3 polymorphism might perturb the delicate balance 
between mood and sleep and the balance toward episodes of 
mania or depression in individuals who have a high genetic 
Table 2 genotypic distribution of the 4-/5-length polymorphism of Per3 in bipolar disorder (BD) type i patients and controls based 
on sex
Group N Genotype, n (%) Allele, n (%) χ2 P
4-/4- 4-/5- 5-/5- 4- 5-
Male control 184 73 (39.7) 90 (48.9) 21 (11.4) 236 (0.64) 132 (0.36) 0.763 0.38
Male BD 152 60 (39.5) 65 (42.8) 27 (17.8) 185 (0.61) 119 (0.39)
Female control 162 68 (41.9) 73 (45.1) 21 (12.9) 209 (0.65) 115 (0.35) 4.532 0.03*
Female BD 159 49 (30.8) 81 (50.9) 29 (18.3) 179 (0.56) 139 (0.44)
Notes: 4-, 4-repeat allele; 5-, 5-repeat allele; *statistically significant.
Abbreviations: N, number of samples; n, number of genotypes and alleles.
Table 3 genotypic distribution of the 4-/5-length polymorphism of Per3 in schizophrenia patients and controls based on sex
Group N Genotype, n (%) Allele, n (%) χ2 P
4-/4- 4-/5- 5-/5- 4- 5-
Male control 184 73 (39.7) 90 (49) 21 (11.3) 236 (0.64) 132 (0.36) 0.373 0.54
Male schizophrenia 180 68 (37.8) 87 (48.3) 25 (13.9) 223 (0.62) 137 (0.38)
Female control 162 68 (42.0) 73 (45) 21 (13.0) 209 (0.65) 115 (0.35) 0.036 0.84
Female schizophrenia 113 47 (41.6) 50 (44.3) 16 (14.1) 144 (0.64) 82 (0.36)
Notes: 4-, 4-repeat allele; 5-, 5-repeat allele.
Abbreviations: N, number of samples; n, number of genotypes and alleles.
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 loading toward BD. This suggestion is consistent with pre-
vious findings that certain genotypes and alleles are more 
vulnerable to schedule changes and that this interaction can 
have behavioral and health-related consequences.37
The foregoing results in schizophrenic patients are in 
accordance with an earlier report that showed no correlation 
between Per3 repeat polymorphism and schizophrenia in a 
Chinese sample.23 Indeed, the onset of schizophrenia was not 
correlated with Per3 or the Clock gene variant, although a 
significant association of Clock allele frequency was found 
in a schizophrenic sample.23 It should be noted that elevated 
levels of interleukin-6 have been observed in individuals 
affected with schizophrenia and a correlation of Per3 repeat 
alleles with interleukin-6 concentration was reported.38 These 
observations underscore the necessity for additional studies in 
larger samples and of different ethnic composition to further 
substantiate the conclusion that a lack of association between 
Per3 repeat alleles and schizophrenia truly exists.
Prevalence of Per3 repeat variants is hypothesized 
to augment phosphorylation of PER (PERIOD) proteins. 
Polymorphic repeats consist of sites for phosphorylation 
and a differential level of phosphorylation is caused by the 
insertion of an additional repeat.16 The present findings of 
an association of Per3 polymorphism with BD-I, but not 
with schizophrenia, are consistent with models suggesting 
that these represent different genres of psychiatric disorders. 
The findings further suggest that clock genes are complexly 
involved in either the expression and/or maintenance of these 
disorders. Furthermore, changes observed in the circadian 
phase of schizophrenia are quite distinct from the phase pat-
tern of BD.9 This implies that the symptoms and pathogenesis 
of schizophrenia and BD are different and have a specific 
relationship with the circadian clock.
The study presented here suffered from several limita-
tions. India comprises multi-ethnic groups and the possible 
impact of population stratification in genetic association 
studies must be taken into consideration.39 Population 
stratification raises the necessity for its confirmation in larger 
samples of patients and in different ethnic populations of 
the Indian subcontinent. Indeed, major genetic studies in 
the world have been carried out without considering the 
large Indian population and its different ethnicities.40 Since 
the controls were recruited from among hospital staff and 
students, an important bias could be that these subjects had 
higher levels of education and cognitive performance than 
patients. In addition, the present study gives no information 
on the association of the onset of BD-I among patients with 
the genotypic variants of Per3. Such a study is needed to 
support a direct link of the polymorphic variants observed 
with BD. Another disadvantage of the study is that it does 
not analyze the association between Per3 polymorphism and 
specific sleep behavior in the same population.
In any event, the data presented are compatible with 
the hypothesis that a length polymorphism in the circadian 
clock gene Per3 influences the pathogenesis of BD-I but not 
of schizophrenia.
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